You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Liposomal doxorubicin

Showing 1 - 25 of 2,209
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Breast Cancer With Liposomal Doxorubicin Regimen

Recruiting
  • Breast Cancer
  • +4 more
  • Liposomal doxorubicin containing regimen
  • Hangzhou, Zhejiang, China
    Second Affiliate Hospital of Zhejiang University
Feb 7, 2023

Metastatic Leiomyosarcoma, Metastatic Sarcoma, Metastatic Soft Tissue Sarcoma Trial (Computed Tomography, Magnetic Resonance

Not yet recruiting
  • Metastatic Leiomyosarcoma
  • +5 more
  • Computed Tomography
  • +3 more
  • (no location specified)
Feb 2, 2023

Platinum-resistant Ovarian Cancer

Not yet recruiting
  • Ovarian Cancer
  • pegylated liposomal doxorubicin
  • (no location specified)
Aug 2, 2023

Kaposi Sarcoma, HIV-1-infection Trial (Pegylated liposomal doxorubicin, Paclitaxel)

Not yet recruiting
  • Kaposi Sarcoma
  • HIV-1-infection
  • (no location specified)
Jan 20, 2023

Ovarian Cancer Recurrent Trial in Beijing (IN10018, Placebo of IN10018, Pegylated Liposomal Doxorubicin)

Recruiting
  • Ovarian Cancer Recurrent
  • Beijing, China
    Cancer Hospital Chinese Academy of Medical Science and Peking Un
Aug 23, 2023

Angiosarcoma Metastatic Trial in Guangzhou (Abraxane combined with liposomal doxorubicin)

Recruiting
  • Angiosarcoma Metastatic
  • Abraxane combined with liposomal doxorubicin
  • Guangzhou, Guangdong, China
    Xing Zhang
Sep 4, 2022

Breast Cancer Trial in Shanghai (Pegylated liposomal doxorubicin, Epirubicin, Cyclophosphamid)

Recruiting
  • Breast Cancer
  • Pegylated liposomal doxorubicin
  • +5 more
  • Shanghai, China
    Shanghai Pudong Hospital
Dec 11, 2022

Recurrent Ovarian Cancer Trial (DOXIL, Withaferin A, Ashwagandha)

Not yet recruiting
  • Recurrent Ovarian Cancer
  • (no location specified)
Jan 27, 2023

Triple Negative Breast Cancer (TNBC) Trial in United States (Combination of liposomal doxorubicin)

Not yet recruiting
  • Triple Negative Breast Cancer (TNBC)
  • Combination of liposomal doxorubicin
  • Elizabeth, New Jersey
  • +7 more
Jul 13, 2023

Colon Cancer Liver Metastasis Trial in United States (Lyso-Thermosensitive Liposomal Doxorubicin, 5% Dextrose Solution,

Terminated
Has Results
  • Colon Cancer Liver Metastasis
  • Lyso-Thermosensitive Liposomal Doxorubicin
  • +2 more
  • Los Angeles, California
  • +3 more
Sep 15, 2022

Relapsed Sarcomas Trial in Cleveland (Disulfiram, Copper Gluconate, Liposomal Doxorubicin (Doxil))

Not yet recruiting
  • Relapsed Sarcomas
  • Cleveland, Ohio
    Cleveland Clinic, Case Comprehensive Cancer Center
Apr 18, 2022

Ovarian Cancer Trial in Pittsburgh (Pembrolizumab, ALX148, Doxorubicin)

Not yet recruiting
  • Ovarian Cancer
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Jul 19, 2022

Advanced Malignant Tumors Trial in Shanghai (doxorubicin HCl liposome injection)

Recruiting
  • Advanced Malignant Tumors
  • doxorubicin hydrochloride liposome injection
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Apr 28, 2022

Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma Trial in

Recruiting
  • Fallopian Tube Carcinosarcoma
  • +28 more
  • Pegylated Liposomal Doxorubicin Hydrochloride
  • Peposertib
  • Aurora, Colorado
  • +7 more
Sep 2, 2022

Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma Trial in Phoenix,

Recruiting
  • Recurrent Fallopian Tube Carcinoma
  • +2 more
  • Bevacizumab
  • +4 more
  • Phoenix, Arizona
  • +2 more
Jun 27, 2022

Breast Cancer Trial in Paris, Barcelone, Madrid (Trastuzumab and non-pegylated liposomal doxorubicin)

Completed
Has Results
  • Breast Cancer
  • Trastuzumab and non-pegylated liposomal doxorubicin
  • Paris, France
  • +3 more
Feb 8, 2022

Breast Cancer Trial in Shanghai (sintilimab, bevacizumab biosimilar, pegylated liposomal doxorubicin)

Recruiting
  • Breast Cancer
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
May 22, 2022

Invasive Breast Carcinoma, Triple-Negative Breast Carcinoma Trial in Houston (biological, drug, other)

Active, not recruiting
  • Invasive Breast Carcinoma
  • Triple-Negative Breast Carcinoma
  • Bevacizumab
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Feb 18, 2022

Advanced Ovarian Cancer Trial in Spain (Olaparib, Pegylated Liposomal Doxorubicin)

Completed
  • Advanced Ovarian Cancer
  • Sabadell, Barcelona, Spain
  • +7 more
Jan 25, 2023

Desmoid Tumor Trial in GuangZhou (Liposome doxorubicin, Saline Solution)

Recruiting
  • Desmoid Tumor
  • Liposome doxorubicin
  • Saline Solution
  • GuangZhou, Guangdong, China
    Sun Yat-sen University cancer center
Sep 29, 2022

Breast Cancer Trial in Tucson, Albuquerque (Pegylated liposomal doxorubicin)

Completed
  • Breast Cancer
  • Pegylated liposomal doxorubicin
  • Tucson, Arizona
  • +1 more
Jan 9, 2023

Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma, Platinum-Refractory Primary Peritoneal

Recruiting
  • Platinum-Refractory Fallopian Tube Carcinoma
  • +11 more
  • Copanlisib Hydrochloride
  • +4 more
  • Aurora, Colorado
  • +2 more
Dec 8, 2022

Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma Trial (procedure, drug, biological, radiation, other)

Not yet recruiting
  • Recurrent Classic Hodgkin Lymphoma
  • Refractory Classic Hodgkin Lymphoma
  • Autologous Hematopoietic Stem Cell Transplantation
  • +13 more
  • (no location specified)
Feb 2, 2023

Liposomal Doxorubicin Induced Hypersensitivity Reaction in Breast Cancer Patients Trial in Guangzhou (Blood sampling)

Recruiting
  • Liposomal Doxorubicin Induced Hypersensitivity Reaction in Breast Cancer Patients
  • Blood sampling
  • Guangzhou, Guangdong, China
    Sun Yat-sen Memorial Hospital
Dec 21, 2021

High-Risk Localized Soft Tissue Sarcoma Trial in Shanghai (Pegylated Liposomal Doxorubicin, Doxorubicin, Anti-PD-1 mAb)

Recruiting
  • High-Risk Localized Soft Tissue Sarcoma
  • Pegylated Liposomal Doxorubicin
  • +3 more
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Mar 15, 2023